Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU (DEX PK)
This study has been completed.
Sponsor:
Orion Corporation, Orion Pharma
Information provided by:
Orion Corporation, Orion Pharma
ClinicalTrials.gov Identifier:
NCT00747721
First received: September 4, 2008
Last updated: April 20, 2009
Last verified: April 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study will examine dexmedetomidine levels in the blood of critically ill intensive care patients to understand how it is broken down by the body.
| Condition | Intervention | Phase |
|---|---|---|
|
Pharmacokinetics Sedation |
Drug: Dexmedetomidine |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Pharmacokinetics of Intravenous Dexmedetomidine for Prolonged Infusion in Critically Ill, Ventilated Patients in Intensive Care Unit; an Open, Non-Randomised, Single Centre Study |
Resource links provided by NLM:
Further study details as provided by Orion Corporation, Orion Pharma:
Primary Outcome Measures:
- Pharmacokinetic variables. [ Time Frame: From start of treatment to 48 hr follow-up. ] [ Designated as safety issue: No ]
| Enrollment: | 13 |
| Study Start Date: | September 2008 |
| Study Completion Date: | February 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Dexmedetomidine
|
Drug: Dexmedetomidine
2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent obtained from the patient's legal representative according to local regulations before starting any study procedures other than pre-screening
- Patients sedated and ventilated in ICU for whom sedation is expected to be clinically required for at least 24 hours, as determined by the responsible physician
- Prescribed light to moderate sedation (target RASS = 0 to -3)
Exclusion Criteria:
- Acute severe intracranial or spinal neurological disorder due to vascular causes, infection, intracranial expansion or injury
- Uncompensated acute circulatory failure at screening (severe hypotension with mean arterial pressure(MAP) < 55 mmHg despite vasopressor and inotrope therapy)
- Heart rate (HR) < 50 beats/min for longer than 5 min between screening and starting study treatment
- Atrioventricular (AV)-conduction block II-III (unless pacemaker installed)
- Severe hepatic impairment (e.g. bilirubin > 101 μmol/L)
- Need for continuous muscle relaxation
- Any condition which would significantly interfere with the collection of study data
- Burn injuries or other conditions requiring regular anesthesia or surgery
- Use of centrally acting alpha-2 agonists or antagonists within 24 hours prior to starting the study (e.g. dexmedetomidine, clonidine, tizanidine, apraclonidine and brimonidine)
- Known allergy to dexmedetomidine or any excipients of the study treatment
- Patients who have or are expected to have treatment withdrawn or withheld due to poor prognosis
- Patients receiving sedation for therapeutic indications rather than to tolerate the ventilator (e.g. epilepsy)
- Patients unlikely to require continuous sedation during mechanical ventilation (e.g. Guillain-Barré syndrome)
- Patients who are unlikely to be weaned from mechanical ventilation; e.g. diseases/injuries primarily affecting the neuromuscular function of the respiratory apparatus such as clearly irreversible disease requiring prolonged ventilatory support (e.g. high spinal cord injury or advanced amyotrophic lateral sclerosis)
Contacts and Locations
More Information
No publications provided by Orion Corporation, Orion Pharma
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Andrew Wighton, Orion Corporation, Orion Pharma |
| ClinicalTrials.gov Identifier: | NCT00747721 History of Changes |
| Other Study ID Numbers: | 3005016, EUDRACT: 2008-001646-10 |
| Study First Received: | September 4, 2008 |
| Last Updated: | April 20, 2009 |
| Health Authority: | Finland: Finnish Medicines Agency |
Additional relevant MeSH terms:
|
Dexmedetomidine Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 21, 2013